Keybanc Initiates Coverage On ResMed with Overweight Rating, Announces Price Target of $227
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Brett Fishbin has initiated coverage on ResMed (NYSE:RMD) with an Overweight rating and set a price target of $227.

February 06, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keybanc analyst Brett Fishbin initiated coverage on ResMed with an Overweight rating and a price target of $227.
The initiation of coverage by Keybanc with an Overweight rating and a high price target of $227 is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term. Analyst ratings, especially with a positive outlook, can influence investor perception and stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100